



18 August 2022

## **CanPharma secures Dronabinol supply for Germany**

### **Highlights**

- **Health House International's German subsidiary, CanPharma, has signed a supply arrangement to access the cannabis extract, dronabinol.**
- **Dronabinol is a formulation of pure-THC, the active ingredient in cannabis, that is widely prescribed in Germany**
- **CanPharma will be able to enter framework agreements with statutory health insurance funds on competitive terms**

Health House International Limited (ASX:HHI) (Health House or the Company, together with the entities it controls the Group) is pleased to announce that its wholly-owned subsidiary CanPharma GmbH ("CanPharma") has secured the supply of the cannabis extract, dronabinol.

Dronabinol is a formulation consisting of pure THC, the active ingredient in cannabis. Dronabinol was the first cannabis compound available in the German market and forms a mainstay of German prescriptions.

As previously announced, CanPharma will be a preferred supplier to a number of statutory health insurance ("SHI") funds for a selection of its CanPharma branded flowers and extracts.

This new source of supply will enable CanPharma to enter into further framework agreements with SHIs for dronabinol on competitive terms.

**CanPharma Chief Executive Officer, and Health House Executive Director, Dr Henrik Sprengel, said** *"This agreement allows us to access a supply of dronabinol on favourable terms which we believe will place us in a strong position for further framework agreements with SHIs."*

**Health House Chief Executive Officer, David Attwood said:** *“We are pleased that CanPharma has been able to expand its range to include dronabinol, a core product for the market. The requirement for GMP manufacturing licence from statutory health insurers gives us an advantage compared to most players when it comes to bidding on further contracts”.*

In Germany public healthcare is provided through SHI funds that cover 90% of the population, with the remainder being covered by private health insurance companies. CanPharma is one of the few German cannabis companies eligible to join framework contracts with insurers due to its GMP manufacturing licence.

This announcement has been approved and authorised for release by the board of Health House International Limited.

**David Attwood**  
**Chief Executive Officer**

**About Health House ([www.healthhouse.com.au](http://www.healthhouse.com.au))**

Health House International and the entities it controls (**the Group**) is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Group is a fully licenced and regulated specialised importer, exporter and distributor currently distributing medicinal cannabis products from 14 producers to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. In the UK and Germany, the Group holds all relevant licences (including GMP manufacturing), Wholesale Dealers and Controlled Drugs licences the Company supplies pharmacies, hospitals, government departments and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe. The Group also integrates education of patients and healthcare professionals in the use of medicinal cannabis as a core part of its activities and is developing digital tools to enable a holistic understanding of usage.

**Address**

Level 3, 101 St Georges Tce  
Perth WA 6000  
AUSTRALIA  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
E: [admin@healthhouse.com.au](mailto:admin@healthhouse.com.au)  
W: [www.healthhouse.com.au](http://www.healthhouse.com.au)  
ACN 149 197 651

**Contact:**

David Attwood  
[David.attwood@healthhouse.com.au](mailto:David.attwood@healthhouse.com.au)  
  
Tim Slate  
[Tim.slate@healthhouse.com.au](mailto:Tim.slate@healthhouse.com.au)